Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Roche (RHHBY) has announced a strategic collaboration with Broad Clinical Labs to develop and implement applications using Roche's next-generation Sequencing By Expansion (SBX) technology. The initial focus will be on trio-based whole genome sequencing for critically ill newborns and their biological parents in neonatal intensive care units (NICUs), aiming to enable faster diagnosis of genetic disorders.
The collaboration will explore integrating SBX technology into routine clinical practice and research applications. The technology offers ultra-fast turnaround times, exceptional scalability, and cost efficiency. Additionally, the partnership will investigate SBX capabilities for RNA sequencing, including bulk and single-cell approaches, to gain novel molecular insights for disease understanding and therapeutic target identification.
- 89% of complete responders were alive one year post-treatment - 82% maintained remission after one year - 58.5% complete remission rate (vs 25.3% in control group) - 59% reduction in disease progression/death risk
The Columvi combination is now approved in over 30 countries for R/R DLBCL patients who aren't candidates for autologous stem cell transplant. The treatment's safety profile remained consistent with previous analyses, with cytokine release syndrome being a common but generally low-grade adverse event.
Roche (RHHBY) has received FDA approval for its VENTANA MET (SP44) RxDx Assay, marking it as the first companion diagnostic test to identify non-squamous non-small cell lung cancer (NSQ-NSCLC) patients eligible for AbbVie's Emrelis treatment. The assay detects MET protein expression, a crucial biomarker for determining patient response to c-Met-targeted therapy.
The approval is backed by the Phase 2 LUMINOSITY study, which demonstrated a 35% overall response rate and 7.2 months median duration of response in patients with high c-Met protein expression treated with Emrelis. This development is particularly significant as approximately 25% of advanced NSCLC patients with normal EGFR genes show high MET protein levels.